Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients
Background and objectives: The short-term reported antibody response to SARS-COV-2 vaccination in dialysis patients is high, with a seroconversion response rate up to 97%. Data on the long-term durability of this response are scarce. Our objective was to characterize the long-term anti-spike antibod...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/1/64 |
| _version_ | 1797498687089278976 |
|---|---|
| author | Noa Berar-Yanay Sarit Freiman Maʹanit Shapira Amer Saffoury Ameer Elemy Munir Hamze Mohamad Elhaj Maha Zaher Loai Matanis Zaher Anis Armaly |
| author_facet | Noa Berar-Yanay Sarit Freiman Maʹanit Shapira Amer Saffoury Ameer Elemy Munir Hamze Mohamad Elhaj Maha Zaher Loai Matanis Zaher Anis Armaly |
| author_sort | Noa Berar-Yanay |
| collection | DOAJ |
| description | Background and objectives: The short-term reported antibody response to SARS-COV-2 vaccination in dialysis patients is high, with a seroconversion response rate up to 97%. Data on the long-term durability of this response are scarce. Our objective was to characterize the long-term anti-spike antibody level in dialysis patients. Design, setting, participants, and measurements: In an observational study, we measured SARS-COV-2 anti-spike antibody levels in dialysis patients who completed 2 doses of the BNT162b2 mRNA SAR S-COV-2 vaccine at 1, 3 and 6 months after the second vaccine dose. We compared the response to dialysis patients who were infected with COVD-19 and to a control group of healthcare-employees. Results: One hundred and forty-two dialysis patients who had been vaccinated (ages 64 ± 11.9 years, 61% male), 33 dialysis patients who had COVID-19 infection (ages 54 ± 14.3 years, 55% male) and 104 individuals in the control group (ages 50 ± 12.2 years, 44% male) were included. The response rate in the vaccinated dialysis patients was 94%, 78% and 73% at 1, 3 and 6 months after the second vaccine dose. In the COVID-19 infected dialysis group and in the control group, the response rate remained at 100% over 6 months. The percentage of change in antibody levels between one and 6 months was −66% in the vaccinated dialysis group, −28% in the control group (<i>p</i> < 0.001) and +48% in dialysis patients who had been infected with COVID-19 (<i>p</i> < 0.001). A non-responder status at 6 months was associated with a lower albumin level. No serious adverse events following vaccination were reported. <b>In conclusion:</b> the initially high response rate to the BNT162b2 vaccine in dialysis patients decreases rapidly. Our results indicate that an early booster (3rd) dose, at three months after the second dose, may be advised for this population to preserve the humoral immunity. |
| first_indexed | 2024-03-10T03:36:55Z |
| format | Article |
| id | doaj.art-a0ef7ef0f49f4d38be8daf6718a0409e |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T03:36:55Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-a0ef7ef0f49f4d38be8daf6718a0409e2023-11-23T11:43:01ZengMDPI AGJournal of Clinical Medicine2077-03832021-12-011116410.3390/jcm11010064Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis PatientsNoa Berar-Yanay0Sarit Freiman1Maʹanit Shapira2Amer Saffoury3Ameer Elemy4Munir Hamze5Mohamad Elhaj6Maha Zaher7Loai Matanis8Zaher Anis Armaly9Department of Nephrology, Hillel Yaffe Medical Center, Hadera 38100, IsraelLaboratory Division Hillel Yaffe Medical Center, Hadera 38100, IsraelLaboratory Division Hillel Yaffe Medical Center, Hadera 38100, IsraelDepartment of Victory-COVID-19, Nazareth Hospital, EMMS, Nazareth 19152, IsraelDepartment of Victory-COVID-19, Nazareth Hospital, EMMS, Nazareth 19152, IsraelDepartment of Nephrology and hypertension, Nazareth Hospital, EMMS, Nazareth 19152, IsraelDepartment of Nephrology and hypertension, Nazareth Hospital, EMMS, Nazareth 19152, IsraelDepartment of Nephrology and hypertension, Nazareth Hospital, EMMS, Nazareth 19152, IsraelDepartment of Nephrology and hypertension, Nazareth Hospital, EMMS, Nazareth 19152, IsraelAzrieli Faculty of Medicine, Bar-Ilan University, Safed 52100, IsraelBackground and objectives: The short-term reported antibody response to SARS-COV-2 vaccination in dialysis patients is high, with a seroconversion response rate up to 97%. Data on the long-term durability of this response are scarce. Our objective was to characterize the long-term anti-spike antibody level in dialysis patients. Design, setting, participants, and measurements: In an observational study, we measured SARS-COV-2 anti-spike antibody levels in dialysis patients who completed 2 doses of the BNT162b2 mRNA SAR S-COV-2 vaccine at 1, 3 and 6 months after the second vaccine dose. We compared the response to dialysis patients who were infected with COVD-19 and to a control group of healthcare-employees. Results: One hundred and forty-two dialysis patients who had been vaccinated (ages 64 ± 11.9 years, 61% male), 33 dialysis patients who had COVID-19 infection (ages 54 ± 14.3 years, 55% male) and 104 individuals in the control group (ages 50 ± 12.2 years, 44% male) were included. The response rate in the vaccinated dialysis patients was 94%, 78% and 73% at 1, 3 and 6 months after the second vaccine dose. In the COVID-19 infected dialysis group and in the control group, the response rate remained at 100% over 6 months. The percentage of change in antibody levels between one and 6 months was −66% in the vaccinated dialysis group, −28% in the control group (<i>p</i> < 0.001) and +48% in dialysis patients who had been infected with COVID-19 (<i>p</i> < 0.001). A non-responder status at 6 months was associated with a lower albumin level. No serious adverse events following vaccination were reported. <b>In conclusion:</b> the initially high response rate to the BNT162b2 vaccine in dialysis patients decreases rapidly. Our results indicate that an early booster (3rd) dose, at three months after the second dose, may be advised for this population to preserve the humoral immunity.https://www.mdpi.com/2077-0383/11/1/64SAR S-COV-2BNT162b2 mRNA vaccineend stage renal diseasedialysiswaning |
| spellingShingle | Noa Berar-Yanay Sarit Freiman Maʹanit Shapira Amer Saffoury Ameer Elemy Munir Hamze Mohamad Elhaj Maha Zaher Loai Matanis Zaher Anis Armaly Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients Journal of Clinical Medicine SAR S-COV-2 BNT162b2 mRNA vaccine end stage renal disease dialysis waning |
| title | Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients |
| title_full | Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients |
| title_fullStr | Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients |
| title_full_unstemmed | Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients |
| title_short | Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients |
| title_sort | waning humoral response 3 to 6 months after vaccination with the sars cov 2 bnt162b2 mrna vaccine in dialysis patients |
| topic | SAR S-COV-2 BNT162b2 mRNA vaccine end stage renal disease dialysis waning |
| url | https://www.mdpi.com/2077-0383/11/1/64 |
| work_keys_str_mv | AT noaberaryanay waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT saritfreiman waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT maʹanitshapira waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT amersaffoury waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT ameerelemy waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT munirhamze waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT mohamadelhaj waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT mahazaher waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT loaimatanis waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT zaheranisarmaly waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients |